SeeThruEquity Issues Update on BioSig Technologies Highlighting Companys Technology Being Featured in Mayo Clinic Research

NEW YORK, NY / ACCESSWIRE / August 18, 2016 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has issued an update note on BioSig Technologies (OTCQB:BSGM).
The report is available here: BSGM August 2016 Update Note.
“We see the publication as a major milestone for BioSig, introducing the technology to the industry through research conducted with the Mayo Clinic, one of the most prestigious institutions in medicine. We see the article as evidence management is making progress on its stated goals for 2016, and we are looking forward to additional peer-reviewed journals and industry presentations in the future,” commented Ajay Tandon, CEO of SeeThruEquity.
Additional highlights from the update include the following:
BioSig achieves major milestone with publication along with Mayo Clinic in leading peer-reviewed publication JACC
BioSig management had stated in an annual letter to investors and stakeholders that it would be introducing the PURE EP System™ to leading industry participants in 2016, and the company continues to follow through on this commitment. In early August, BioSig announced that its lead device, the PURE EP System™, was featured in a research article by researchers from the prestigious Mayo Clinic that was published in The Journal of the American College of Cardiology (JACC): Clinical Electrophysiology, a leading peer-reviewed publication focused on care and heart health in the area of cardiac electrophysiology. Authored by Dr. Samuel Asirvatham, Vice Chair of Cardiovascular Diseases and program director of Clinical Cardiac Electrophysiology Training Program at the Mayo Clinic in Rochester, MN, the article represents the first piece about PURE EP™ in a peer-reviewed publication and is a significant milestone for the company.
Article highlights advantages versus standard EP recording systems
BioSig’s PURE EP System is a high fidelity surface electrocardiogram (ECG) and intracardiac multichannel recording and analysis system, which is designed to improve the process of identifying catheter ablation targets – areas of tissue to destroy that otherwise create a cardiac arrhythmia. The article appearing in JACC: Clinical Electrophysiology featuring BioSig’s PURE EP™ was entitled “Novel Electrophysiology Signal Recording System Enables Specific Visualization of the Purkinje Network and Other High-Frequency Signals” and highlighted the advantages of BioSig’s proprietary PURE EP™ technology versus standard EP recording systems, particularly for the analysis of high frequency signals (ie, Purkinjie potentials). Dr. Asirvatham also noted PURE EP’s capability to show the same channel with different processing options, enabling doctors to highlight specific features while still displaying the original electrogram signal. In our view, the article is a major event for the company, providing peer-reviewed journal validation for the company’s innovative approach to a $3.5 billion market opportunity while elevating its profile and garner increased industry attention to the advantages of the PURE EP™ System.
Maintain price target of $3.53 for BioSig
We have been encouraged by the progress made by BioSig since our initiation of coverage in February 2016 and note that shares have risen by more than 25% in that time. We see several opportunities ahead for BioSig and are maintaining a price target of $3.53 at this time.
Connect with BioSig Technologies (OTCQB:BSGM) to receive an Investor Presentation.